Olopatadine (Opatanol)
Is It Right for You?
A complete guide to Olopatadine (Opatanol) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Olopatadine (Opatanol)?
Olopatadine hydrochloride, marketed as Opatanol, is a dual-acting antiallergic ophthalmic solution available as 0.1% eye drops (Opatanol) for twice-daily dosing and as a higher-concentration 0.2% formulation (Pataday) for once-daily use. It belongs to a class of antihistamines specifically formulated for ocular use and is among the most effective topical treatments for allergic conjunctivitis.
Olopatadine is distinctive for its dual mechanism: it is a potent, selective histamine H1 receptor antagonist and a mast cell stabiliser — addressing both the immediate-phase allergic response and preventing the release of histamine and other inflammatory mediators from conjunctival mast cells. This dual action makes it more comprehensively effective than either antihistamines or mast cell stabilisers used alone.
Opatanol 0.1% is a prescription-only medication in the UK. Higher-concentration formulations and some alternative brands may have different regulatory status. A clinician should confirm the diagnosis and exclude other causes of red, itchy eyes before prescribing.
What Conditions Is Olopatadine Used For?
Olopatadine is indicated for:
relief of ocular symptoms of seasonal allergic conjunctivitis, including itching, redness, watering, and eyelid swelling, triggered by seasonal allergens such as grass pollen, tree pollen, and mould spores
management of year-round allergic ocular symptoms triggered by persistent allergens such as house dust mite, animal dander, and mould
used as part of management in this more severe, predominantly paediatric allergic eye disease under specialist supervision
Olopatadine effectively controls the ocular symptoms of allergic conjunctivitis but does not modify the underlying allergic sensitisation. Allergen avoidance strategies and, where appropriate, allergen immunotherapy (desensitisation) address the root cause. For patients with severe or refractory allergic eye disease, referral to an ophthalmologist or allergy specialist should be considered.
How Does Olopatadine Work?
Olopatadine's clinical efficacy derives from its complementary dual mechanism targeting the type I IgE-mediated allergic response in the conjunctiva:
Histamine H1 receptor antagonism: When an allergen contacts the conjunctival surface in a sensitised patient, IgE antibodies on mast cells cross-link, triggering rapid degranulation and the release of histamine. Histamine binds to H1 receptors on conjunctival blood vessels and sensory nerve fibres, causing the characteristic itch, redness, tearing, and swelling of allergic conjunctivitis. Olopatadine competitively and selectively blocks H1 receptors on the ocular surface, preventing histamine from exerting these effects.
Mast cell stabilisation: Olopatadine inhibits the IgE-mediated degranulation of conjunctival mast cells, preventing the release of histamine and other pro-inflammatory mediators (including prostaglandins, leukotrienes, and cytokines) before they are secreted. This mast cell stabilising effect not only addresses the immediate allergic response but also attenuates the late-phase inflammatory response — the sustained inflammation that follows the immediate reaction hours later.
Selectivity: Olopatadine is highly selective for H1 receptors and has minimal affinity for other receptor types (including H2, muscarinic, alpha-adrenergic, and dopamine receptors), which accounts for its very favourable local and systemic tolerability profile.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Wash hands thoroughly before instilling eye drops. Avoid contaminating the dropper tip by touching the eye, eyelashes, or any surface.
Tilt the head back, pull down the lower eyelid, and instil one drop into the lower conjunctival sac. Close the eye gently for 1–2 minutes and apply gentle pressure to the inner corner of the eye (nasolacrimal occlusion) to reduce systemic absorption and maximise ocular contact time.
Wait at least 5 minutes between different eye drops if using more than one ophthalmic preparation.
Remove contact lenses before instillation. Wait at least 10–15 minutes before reinserting lenses, as the preservative (benzalkonium chloride) in the 0.1% formulation can be absorbed by soft contact lenses and may cause irritation.
Use consistently throughout the allergy season. For best results, olopatadine should be used regularly — not just when symptoms are at their worst — as the mast cell stabilising component works best when applied before allergen exposure.
Store at room temperature and discard within 4 weeks of opening.
Side Effects of Olopatadine
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Transient mild stinging or burning on instillation --- very common; usually resolves within seconds
- Mild, transient blurring of vision immediately after instillation
- Headache (reported in clinical trials)
- Dry eye sensation
- Taste disturbance --- due to drainage of drops through the nasolacrimal duct
- Severe hypersensitivity reaction --- including allergic contact dermatitis of the eyelid, angioedema, or anaphylaxis; rare
- Corneal toxicity --- rare; associated primarily with preservative (benzalkonium chloride) in chronic use; consider preservative-free formulations in patients using multiple preserved eye drops or wearing contact lenses frequently
- Raised intraocular pressure --- not an expected effect of olopatadine specifically, but any unexplained eye pain, redness, or visual change during treatment should be assessed promptly by a clinician to exclude other pathology
Benzalkonium chloride, the preservative in the standard Opatanol 0.1% formulation, is absorbed by soft contact lenses and can cause ocular surface irritation. Lenses must be removed before instillation and not reinserted for at least 10–15 minutes. Patients using contact lenses who require long-term treatment should discuss preservative-free formulations with their clinician.
Drug Interactions
Olopatadine has negligible systemic absorption from correctly applied topical formulations, meaning significant pharmacokinetic interactions with systemic drugs are not expected. However, do not apply other creams or emollients immediately before olopatadine application as they may dilute and reduce efficacy.
no clinically significant pharmacokinetic interactions; when using multiple eye drops, allow at least 5 minutes between each preparation to prevent dilution and washout of the first drop.
concurrent oral and topical antihistamine use does not typically cause clinical problems at standard doses; theoretical additive anticholinergic effects are not clinically relevant at olopatadine's low systemic absorption levels.
benzalkonium chloride (the preservative) is absorbed by soft contact lens materials; this is a pharmaceutical interaction with the lens rather than a systemic drug interaction.
Important Warnings
Olopatadine is not indicated for red or irritated eyes caused by contact lens overwear, contact lens solution reactions, or dry eye. It is specifically indicated for allergic conjunctivitis. Using it for other causes of red eye may mask symptoms of a different, potentially serious condition.
New eye pain, photophobia, significantly worsening redness, or any change in vision during treatment with olopatadine must be assessed by a clinician or ophthalmologist promptly. These symptoms may indicate a condition unrelated to allergy — such as keratitis, iritis, or glaucoma — that requires different management.
Benzalkonium chloride, the preservative in standard Opatanol drops, can cause ocular surface irritation in patients with dry eye disease or those using multiple preserved eye drops. Preservative-free formulations are available and should be considered in these patients.
Olopatadine 0.1% is licensed for use in children aged 3 years and over. Use in younger children should be under specialist guidance.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Olopatadine FAQs
The antihistamine component of olopatadine begins to relieve itch within minutes of instillation. The mast cell stabilising effect, which helps prevent the allergic response from being triggered, builds up with regular daily use. For best results during allergy season, use olopatadine consistently every day rather than only on symptomatic days.
You must remove soft contact lenses before instilling Opatanol drops and wait at least 10–15 minutes before reinserting them. The preservative benzalkonium chloride is absorbed by soft lens materials and can cause irritation. If you wear contact lenses regularly, ask your clinician or optometrist about preservative-free olopatadine formulations.
Regular daily use throughout your allergy season provides better symptom control than reactive use. The mast cell stabilising component is most effective when used prophylactically, preventing mast cell degranulation before allergen exposure rather than only managing symptoms after they have occurred.
Yes — olopatadine eye drops and oral antihistamines (such as cetirizine or loratadine) are frequently used together for patients with both ocular and systemic allergic symptoms. They work via complementary routes and there is no clinically significant interaction at standard doses
Persistent or worsening redness, pain, photophobia, or any change in vision despite olopatadine treatment requires prompt clinical or ophthalmological review. These symptoms may indicate a non-allergic condition — such as dry eye disease, bacterial conjunctivitis, keratitis, or uveitis — that requires different treatment. Do not assume all red eye is allergic in origin.